Focal Segmental Sclerosis Associated with the Novel Multi-tyrosine Kinase Inhibitor Ponatinib

  • Arai Hiroyuki
    Department of Nephrology, Kyoto University Graduate School of Medicine, Japan
  • Yamamoto Shinya
    Department of Nephrology, Kyoto University Graduate School of Medicine, Japan
  • Matsubara Takeshi
    Department of Nephrology, Kyoto University Graduate School of Medicine, Japan
  • Miyake Takafumi
    Department of Nephrology, Kyoto University Graduate School of Medicine, Japan
  • Tochio Akira
    Department of Nephrology, Kyoto University Graduate School of Medicine, Japan Department of Nephrology, Japanese Red Cross Society Wakayama Medical Center, Japan
  • Mii Akiko
    Department of Nephrology, Nippon Medical School, Japan
  • Shimizu Akira
    Department of Analytic Human Pathology, Nippon Medical School, Japan
  • Minamiguchi Sachiko
    Department of Diagnostic Pathology, Kyoto University Hospital, Japan
  • Muso Eri
    Division of Nephrology and Dialysis, Kitano Hospital, Japan Department of Food and Nutrition, Faculty of Contemporary Home Economics, Kyoto Kacho University, Japan
  • Yanagita Motoko
    Department of Nephrology, Kyoto University Graduate School of Medicine, Japan Institute for the Advanced Study of Human Biology (ASHBi), Kyoto University, Japan

この論文をさがす

説明

<p>Ponatinib is a novel multi-tyrosine kinase inhibitor (TKI) with potent inhibitory activity against refractory chronic myeloid leukemia (CML). Despite its high clinical efficacy, ponatinib induces various adverse events due to its multi-target characteristic. However, renal complications associated with ponatinib are rare. A 76-year-old woman had a history of chronic myeloid leukemia (CML) resistant to imatinib and nilotinib. Our patient developed proteinuria and renal function deterioration during treatment with ponatinib but not with imatinib or nilotinib. We herein report the first case of a patient with secondary focal segmental glomerulosclerosis (FSGS) with partial glomerular collapse induced by ponatinib treatment. </p>

収録刊行物

  • Internal Medicine

    Internal Medicine 62 (18), 2693-2698, 2023-09-15

    一般社団法人 日本内科学会

被引用文献 (1)*注記

もっと見る

参考文献 (28)*注記

もっと見る

関連プロジェクト

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ